TB R&D Weekly Update: Podcast Interview with Peter Andersen

[wpaudio url=”/blog/media/podcasts/Andersen_Peter_finished.mp3″ text=”Click here to play the Peter Anderson Podcast” dl=”0″]

Listen to Peter Andersen Podcast

Summary: Dr. Peter Andersen is Vice President of Vaccine Research and Development at Statens Serum Institut (SSI). The WGND had the opportunity to talk with Dr. Andersen on a recent article entitled “A multistage tuberculosis vaccine that confers efficient protection before and after exposure” that we covered in a previous TB R&D Weekly Update. The article is published in Nature Medicine in February 2011. In the interview, Dr. Andersen provides an overview of his present research and the article, possible integration of a vaccine that protects pre- and post- exposure into TB treatment, and the challenges for TB vaccine development.

Additional TB R&D News:

New findings on drug tolerance in TB suggest ideas for shorter cures

BC Scientists Pioneer Method to Trace TB Outbreak

Traditional drug-discovery model ripe for reform

Sterilizing Activity of Second-Line Regimens Containing TMC207 in a Murine Model of Tuberculosis

A multistage tuberculosis vaccine that confers efficient protection before and after exposure

More News
22 Jul 2024
The National Institutes of Health’s National Institute of Allergy and Infectious Diseases (NIAID) has issued a $30.8 million grant to the Preclinical Design and Clinical Translation of TB Regimens (PreDiCTR) consortium , a new consortium co-led by investigators from Weill Cornell Medicine; the...
27 Jun 2024
On May 17, the World Health Organization (WHO) released its updated  Bacterial Priority Pathogens List (BPPL) 2024 and for the first time in its history it included a drug resistant strain of Mycobacterium tuberculosis. Along with three other new families of antibiotic-resistant bacterial pathogens...
19 Mar 2024
For World TB Day 2024, the WGND is spotlighting a monumental achievement in TB drug research and development: the Global TB Drug Pipeline has never been bigger than it is today. The number of drug candidates being clinically evaluated for use in the treatment of adult pulmonary TB has surpassed...